Regadenoson

Pre-clinicalTerminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pulmonary Hypertension

Conditions

Pulmonary Hypertension

Trial Timeline

Aug 1, 2014 → May 25, 2017

NCT ID

NCT02220634

About Regadenoson

Regadenoson is a pre-clinical stage product being developed by Astellas Pharma for Pulmonary Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT02220634. Target conditions include Pulmonary Hypertension.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02697877	Pre-clinical	Completed	Feb 1, 2016	Jul 1, 2018	Coronary Artery Disease
NCT02589977	Approved	Completed	Nov 1, 2015	Jan 21, 2020	Heart Failure, Diastolic
NCT02220634	Pre-clinical	Terminated	Aug 1, 2014	May 25, 2017	Pulmonary Hypertension
NCT01969916	Pre-clinical	Completed	Jun 1, 2014	Jun 1, 2018	Coronary Artery Disease
NCT01779869	Approved	Completed	Jan 1, 2013	Jun 1, 2015	Ischemic Heart Disease
NCT01618669	Phase 3	Completed	Jun 1, 2012	Dec 1, 2014	Coronary Artery Disease (CAD)
NCT01446094	Approved	UNKNOWN	Aug 1, 2011	Jun 1, 2018	Coronary Artery Disease
NCT01334918	Phase 2	Completed	Apr 26, 2011	Jul 2, 2012	Coronary Artery Disease (CAD)
NCT01021618	Pre-clinical	Completed	Jan 1, 2010	Mar 1, 2012	Coronary Artery Disease
NCT01026012	Pre-clinical	Completed	Dec 1, 2009	Sep 1, 2010	Cardiac Function
NCT00881218	Phase 1	Completed	Jun 1, 2009	Dec 1, 2011	Ischemic Heart Disease
NCT00837369	Phase 1	Completed	Apr 7, 2009	Dec 1, 2011	Coronary Artery Disease
NCT00871260	Approved	Completed	Apr 1, 2009	Jun 4, 2014	Coronary Disease
NCT00857792	Pre-clinical	Completed	Mar 1, 2009	Jan 1, 2013	Coronary Disease

Competing Products

20 competing products in Pulmonary Hypertension

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	44
macitentan 10 mg	BML, Inc.	Phase 3	76
tadalafil + tadalafil	Eli Lilly	Phase 3	77
CS1 Administration	Cereno Scientific	Phase 2	47
CS1	Cereno Scientific	Pre-clinical	18
TX000045- Dose A + TX000045- Dose B + Placebo	Tectonic Therapeutic	Phase 2	44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 2	44
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	52
DS-1040b + Placebo + Enoxaparin	Daiichi Sankyo	Phase 1/2	41
DS-9231 + Placebo	Daiichi Sankyo	Phase 2	52
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	52
Monteplase	Eisai	Approved	85
lysozyme 90 mg + Placebo	Eisai	Approved	85
Prednisolone + Voriconazole	Cipla	Phase 2/3	65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)	Eli Lilly	Phase 2	52
tadalafil and ambrisentan upfront combination therapy	Eli Lilly	Approved	85
Tadalafil- Tablet or Oral suspension	Eli Lilly	Phase 1/2	41

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved